Literature DB >> 31732806

Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults.

Christian Thomas1, Annika Wefers2,3, Susanne Bens4, Karolina Nemes5, Abbas Agaimy6, Florian Oyen7, Silke Vogelgesang8, Fausto J Rodriguez9, Francesca M Brett10, Roger McLendon11, Istvan Bodi12, Fanny Burel-Vandenbos13, Kathy Keyvani14, Stefan Tippelt15, Frantz R Poulsen16, Eric S Lipp17, Caterina Giannini18, Guido Reifenberger19,20, Klaus Kuchelmeister21, Torsten Pietsch21, Uwe Kordes7, Reiner Siebert4, Michael C Frühwald5, Pascal D Johann22,23, Martin Sill22,23, Marcel Kool22,23, Andreas von Deimling2,3, Werner Paulus1, Martin Hasselblatt24.   

Abstract

Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly occurring in infants. Mutations of the SMARCB1 gene are the characteristic genetic lesion. SMARCB1-mutant tumors in adolescents and adults are rare and may show uncommon histopathological and clinical features. Here we report seven SMARCB1-deficient intracranial tumors sharing distinct clinical, histopathological and molecular features. Median age of the four females and three males was 40 years (range 15-61 years). All tumors were located in the pineal region. Histopathologically, these tumors displayed spindled and epithelioid cells embedded in a desmoplastic stroma alternating with a variable extent of a loose myxoid matrix. All cases showed loss of nuclear SMARCB1/INI1 protein expression, expression of EMA and CD34 was frequent and the Ki67/MIB1 proliferation index was low in the majority of cases (median 3%). Three cases displayed heterozygous SMARCB1 deletions and two cases a homozygous SMARCB1 deletion. On sequencing, one tumor showed a 2 bp deletion in exon 4 (c.369_370del) and one a short duplication in exon 3 (c.237_276dup) both resulting in frameshift mutations. Most DNA methylation profiles were not classifiable using the Heidelberg Brain Tumor Classifier (version v11b4). By unsupervised t-SNE analysis and hierarchical clustering analysis, however, all tumors grouped closely together and showed similarities with ATRT-MYC. After a median observation period of 48 months, three patients were alive with stable disease, whereas one patient experienced tumor progression and three patients had succumbed to disease. In conclusion, our series represents an entity with distinct clinical, histopathological and molecular features showing epigenetic similarities with ATRT-MYC. We propose the designation desmoplastic myxoid tumor (DMT), SMARCB1-mutant, for these tumors.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31732806     DOI: 10.1007/s00401-019-02094-w

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant.

Authors:  Branavan Manoranjan; Abdelsimar T Omar; Hai-Bo Wu; Robert Nordal; Yves P Starreveld
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 12.300

Review 2.  The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

Authors:  Alejandro Perez; Jason T Huse
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 5.081

Review 3.  2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

Authors:  Cillian McNamara; Kshitij Mankad; Stefanie Thust; Luke Dixon; Clara Limback-Stanic; Felice D'Arco; Thomas S Jacques; Ulrike Löbel
Journal:  Neuroradiology       Date:  2022-07-22       Impact factor: 2.995

4.  Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach.

Authors:  Tadanori Tomita; Tord D Alden; Arthur J Dipatri
Journal:  Childs Nerv Syst       Date:  2022-07-11       Impact factor: 1.532

Review 5.  The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know.

Authors:  A G Osborn; D N Louis; T Y Poussaint; L L Linscott; K L Salzman
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-16       Impact factor: 4.966

Review 6.  A case of an atypical teratoid/rhabdoid tumor with distinctive histology in the pineal region in an adult patient.

Authors:  Masatomo Doi; Junki Koike; Yasuyuki Yoshida; Hisao Nakamura; Motohiro Chosokabe; Saeko Naruki; Shinya Tajima; Akira Endo; Takashi Matsumori; Yuichiro Tanaka
Journal:  Pathol Int       Date:  2021-09-02       Impact factor: 2.121

7.  Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.

Authors:  Dörthe Holdhof; Pascal D Johann; Michael Spohn; Michael Bockmayr; Sepehr Safaei; Piyush Joshi; Julien Masliah-Planchon; Ben Ho; Mamy Andrianteranagna; Franck Bourdeaut; Annie Huang; Marcel Kool; Santhosh A Upadhyaya; Anne E Bendel; Daniela Indenbirken; William D Foulkes; Jonathan W Bush; David Creytens; Uwe Kordes; Michael C Frühwald; Martin Hasselblatt; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2020-12-17       Impact factor: 17.088

Review 8.  Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview.

Authors:  Giuseppe Lombardi; Pietro Luigi Poliani; Renzo Manara; Moncef Berhouma; Giuseppe Minniti; Emeline Tabouret; Evangelia Razis; Giulia Cerretti; Vittorina Zagonel; Michael Weller; Ahmed Idbaih
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 9.  A simplified overview of the World Health Organization classification of central nervous system tumors 2021.

Authors:  Hanuman Prasad Prajapati; Sanjay Kumar Kannaujia
Journal:  Surg Neurol Int       Date:  2022-06-17

Review 10.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.